What Daito Pharmaceutical does

Daito Pharmaceutical Co., Ltd. (ダイト株式会社) is a Japanese pharmaceutical manufacturer founded in 1942 and listed on the Tokyo Stock Exchange Prime Market under ticker 4577. The company operates an integrated pharmaceutical manufacturing platform spanning active pharmaceutical ingredient (API) production through finished dosage formulation, including contract development and manufacturing organization (CDMO) services. Its business is organized around five segments: API manufacturing and sale (~45% of consolidated revenue), generic pharmaceutical development and manufacturing (~54% of revenue), prescription drug contract manufacturing, OTC pharmaceuticals, and healthcare products including quasi-drugs and health foods sold through dispensing agents.

The company holds 106 Master File (MF) registrations for APIs — the highest count among Japanese pharmaceutical manufacturers — and maintains quality systems meeting both Japanese GMP and the more stringent U.S. FDA standards. Production capabilities include theoretical capacity of approximately 36 billion tablets and 900 tons of granules annually across 15 production lines, plus dedicated 7th and 8th Formulation Buildings for highly potent drugs including anti-cancer agents. The company is investing in flow synthesis / continuous manufacturing technology as a mid-term strategic initiative. Consolidated headcount stands at approximately 1,073 employees as of FY2025.

Daito generated ¥50.6 billion (approximately $337 million USD) in consolidated sales for the fiscal year ending May 2025, marking 14 consecutive years of revenue growth since its 2010 IPO. The company operates exclusively through third-party distribution channels — it maintains no direct medical representative (MR) sales force and instead routes sales through pharmaceutical wholesalers and sales partners. Its customer base reportedly spans over 90% of Japanese pharmaceutical makers, with international subsidiaries in the United States (Daito Pharmaceuticals America) and China (大桐製薬 / Datong Pharmaceutical (China)). Leadership is headed by President and CEO Matsumori Hiromichi (松森 浩士).

Name

Daito Pharmaceutical

Legal name

Daito Pharmaceutical Co., Ltd.

Website

http://www.daitonet.co.jp/

Company type

Public

Founded year

1942

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Daito Pharmaceutical is a Japanese pharmaceutical manufacturer founded in 1942, producing APIs and generic drugs at scale with FDA-compliant facilities. It serves Japanese and international pharmaceutical makers via contract manufacturing and its own generics portfolio.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Active pharmaceutical ingredients
• Generic drug manufacturing
• Contract pharmaceutical manufacturing
• Prescription drug production
• Pharmaceutical formulation services

Headquarters

HQ city

Toyama-shi

HQ country

Japan

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. 原薬事業: 原薬の製造・販売、輸入及び仕入販売。国内外の厳しい品質基準に適合し、高い生産能力により安定供給を実現。売上高構成比45%。
2. 製剤事業（ジェネリック医薬品）: ジェネリック医薬品の開発・製造・開発販売。主力事業で、合理的な価格で高品質なジェネリック医薬品を安定的に提供。売上高構成比54%。医療費削減効果425億円（2025年5月期）。
3. 医療用医薬品受託製造: ジェネリック医薬品、OTC医薬品の開発から製造までを一括して受託。新薬・長期収載品の受託製造も手がける。
4. OTC医薬品: 一般用医薬品の開発・製造販売。
5. ヘルスケア事業: 健康食品の企画・委託生産的配置業者等への販売。医薬部外品等の医薬関連商品の販売も行う。

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Daito Pharmaceutical manufactures and sells active pharmaceutical ingredients (APIs) and finished formulations. The company manufactures generic pharmaceuticals, conducts contract manufacturing of prescription drugs (including highly potent drugs such as anti-cancer agents), and sells OTC pharmaceuticals and healthcare products. Manufacturing spans from API production through to tablet, granule, and other solid oral dosage form manufacturing, with theoretical capacity of 36 billion tablets per year.

Product overview

Daito Pharmaceutical operates as a Contract Development and Manufacturing Organization (CDMO) with integrated capabilities spanning the pharmaceutical value chain. The company's core business consists of five interconnected segments: (1) Active Pharmaceutical Ingredients (API) manufacturing and sales with 106 registered Master Files - the highest in Japan; (2) Generic Pharmaceuticals development and manufacturing offering high-quality generics at 40-50% of originator prices; (3) Contract manufacturing services for prescription drugs, OTC medicines, and highly potent drugs (including anti-cancer agents); (4) OTC pharmaceuticals; and (5) Healthcare products including health foods. The company also maintains Quality Assurance operations to ensure GMP and FDA compliance. Recent product launches include Capecitabine tablets, Lacosamide formulations, and various other generic drugs distributed through multiple sales partner companies.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (API) Manufacture, sale, import, and resale of active pharmaceutical ingredients (APIs) that serve as the effective components in pharmaceutical products. Conforms to strict domestic and international quality standards, with high production capacity enabling stable supply. APIs account for approximately 45% of consolidated revenue.
• Generic Pharmaceuticals Development, manufacture, and sale of generic pharmaceuticals released after original drug patents expire. Daito offers high-quality generics at reasonable prices (40-50% of originator pricing), with its generic supply contributing ¥42.5 billion in healthcare cost reduction in FY2025. Generics account for approximately 54% of consolidated revenue.
• Contract Manufacturing of Prescription Drugs (CDMO) Contract manufacturing services for prescription pharmaceuticals, including development and manufacturing from generic drugs to OTC medicines. Handles tablet, granule, and other solid oral dosage forms. Contracts for new drugs and long-listed products are also accepted.
• OTC Pharmaceuticals Development, manufacture, and sale of over-the-counter (OTC) pharmaceutical products.
• Healthcare Products
• Highly Potent Drug Manufacturing Specialized manufacturing of highly potent pharmaceutical products including anti-cancer agents, using dedicated 7th and 8th Formulation Buildings with containment technology to prevent worker exposure and environmental release. Includes research and development of high-pharmacological-activity formulations at the High Pharmacology R&D Center completed in June 2017.
• Tablet and Granule Manufacturing
• Quality Assurance Services Quality assurance ensuring pharmaceutical products meet domestic and international standards, including Japanese GMP compliance and FDA standards. Includes 220 personnel in the reliability assurance organization (including Quality Assurance Department and Quality Management Department).

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered minor, core and regional.

• 共創未来ファーマ株式会社minorChannel Partner/ Reseller/ Distributor · 12 June 2026自社製品を他社ブランドで上市する販売パートナー。ビラスチンOD錠やレトロゾール錠など複数の製品を発売している。
• 日本ケミファ株式会社minorChannel Partner/ Reseller/ Distributor · 12 June 2026
• フェルゼンファーマ株式会社minorChannel Partner/ Reseller/ Distributor · 12 June 2026
• 富山大学minorOthers · 22 January 2024富山大学とネーミングライツ・パートナー契約を締結。医薬学図書館内グループ学習室へのパートナー企业提供を通じて地域とのつながりを強化。
• 大和薬品工業株式会社coreOthersダイトの連結子会社。城戸清隆（前代表取締役社長、2025年5月逝去）在籍。石 держав地震（2024年1月）では生产設備に異常は認められず通常操業を継続した。
• Daito Pharmaceuticals America, Inc.regionalOthersダイトの連結子会社（海外）。海外市場への対応体制の一環として设立。
• 大桐製薬（中国）有限責任公司coreOthersダイトの連結子会社。中国・安徽省に所在。原薬の製造委託先であり、将来的には同社の品質レベルで製造した医薬品を中国マーケットで流通させることを検討中。「日本品質・中国コスト」により合理的なコストでの原料・原薬の安定調達を推進。

Scale indicators7 records

Recent moves2 records

Expansion highlights7 records

Direct peers

• Sawai Group Holdings: Japan's largest domestic generic pharmaceutical manufacturer, offering prescription generics, APIs, and contract manufacturing. Closest comparable by business model, customer base (Japanese pharma majors), and product breadth, though Sawai is significantly larger.
• Nichi-Iko Pharmaceutical: Japanese generic drug manufacturer with vertical API/formulation integration, supplying hospitals, pharmacies, and dispensing chains. Direct overlap with Daito in oral solid generics and generic procurement channels.
• Towa Pharmaceutical: Mid-cap Japanese generic manufacturer focused on oral solid dosage forms with integrated API sourcing. Comparable in size, channel strategy (wholesaler-led), and product portfolio mix to Daito.
• ASKA Pharmaceutical: Japanese specialty pharmaceutical manufacturer that combines proprietary branded drugs with generic and contract manufacturing capabilities. Comparable integrated API-to-formulation operating model.
• Fuji Pharma: Japanese specialty pharma with strong positions in women's health, generics, and contract manufacturing. Comparable in combining branded generics, OEM/CMO services, and a domestic hospital-channel GTM.
• Bushu Pharmaceuticals: Japanese CDMO providing formulation development and contract manufacturing of oral solids, similar to Daito's contract manufacturing division. Closest pure-play CDMO comparable.

Broad incumbents

• CMIC Holdings: Japan's largest CRO with CDMO and pharmaceutical businesses. Operates a broader services portfolio (CRO + CDMO + own pharma), overlapping with Daito on the manufacturing-services side.
• Daiichi Sankyo: Global Japanese pharmaceutical major with substantial API and formulation capabilities. Overlaps with Daito as a customer (Daito supplies APIs) and as a competitor in certain generic segments.
• Takeda Pharmaceutical: Japan's largest pharma company with extensive in-house API manufacturing and global generics footprint through its legacy business. Comparable as both a large-scale API/finished drug manufacturer and a potential B2B customer for Daito.

Emerging players

• Aenova: European-headquartered CDMO offering solid oral dosage form development and manufacturing. Comparable as a contract manufacturer of generics and specialty formulations serving originator pharma customers, useful as a global scale benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Daito Pharmaceutical